Novartis settles 18-month-old lawsuit from estate of Baltimore woman whose cells were extracted 75 years ago
On Feb. 24, 2026, The family of a Baltimore woman whose cells were extracted for medical research without…
-
-
Novartis breaks ground on new global Biomedical Research center in San Diego to accelerate drug discovery
On Feb. 6, 2026, Novartis broke ground on a new, state-of-the-art global Biomedical Research center in San Diego,…
-
Novartis to add radioligand therapy manufacturing facility in Winter Park, Florida
On Jan. 9, 2026, Novartis announced plans to build its fourth US radioligand therapy (RLT) manufacturing facility in…
-
Novartis and U.S. government reach agreement on lowering drug prices
On Dec. 19, 2025, Novartis, a leading global innovative medicines company, announced it has reached an agreement with…
-
Novartis announces plans to build flagship manufacturing hub in North Carolina
On Nov. 19, 2025, Novartis, a leading global innovative medicines company, announced plans to expand its operations in…
-
Biotechnology | Disease | FDA | Therapeutics
Sandoz launches TYRUKO® (natalizumab-sztn) in US, as first and only multiple sclerosis biosimilar
On Nov. 17, 2025, Sandoz announced that TYRUKO® (natalizumab-sztn) is available to patients in the US. Developed by…
-
Novartis to acquire Avidity Biosciences, an innovator in RNA therapeutics for $11 Billion
On Oct. 26, 2025, Novartis announced that it has entered into an agreement to acquire Avidity Biosciences, a…
-
Setback for Roche in Natco Pharma case as India Supreme Court allows generic drug sales
On Oct. 18, 2025, the Swiss Pharma giant F Hoffmann La Roche (Roche) suffered a setback as the…
-
ETH Zurich Computer Scientists Create A ‘DNA search engine’
On Aug. 10, 2025, computer scientists at ETH Zurich announced they have developed a digital tool capable of…
-
Dangerous fungal spores can surf the stratosphere—and survive
On May 7, 2025, scientists reported that they have captured fungal spores cruising in the inhospitable environment of…
-
Novartis received FDA approval for Fabhalta (iptacopan) as the first oral monotherapy for adults with PNH
On Dec. 5, 2023, Novartis announced that the U.S. Food and Drug Administration (FDA) had approved Fabhalta (iptacopan)…
-
FDA approved Novartis Cosentyx as the first new biologic treatment for hidradenitis suppurativa patients in a decade
On Oct. 31, 2023, Novartis announced that the US Food and Drug Administration (FDA) had approved Cosentyx (secukinumab)…
-
Special drone collects environmental DNA from trees
On Jan. 19, 2023, researchers at ETH Zurich and the Swiss Federal research institute WSL announced they had…
-
World-first agreement between Novartis and NHS enabled broad access to first-in-class cholesterol-lowering medicine
On Aug. 31, 2021, Novartis announced a commercial agreement with the NHS in England as part of a…
-
Novartis and Molecular Partners announced start of EMPATHY clinical trial for ensovibep for treatment of COVID-19
On May 27, 2021, Novartis and Molecular Partners announced the start of the clinical trial EMPATHY, a Phase…
-
Novartis and Gates Foundation collaborate to discover and develop in vivo gene therapy for sickle cell disease
On Feb. 17, 2021, Novartis announced that it had entered into a grant agreement with the Bill &…
-
At $2M, priciest ever medicine treats fatal genetic disease
On May 24, 2019, U.S. regulators have approved the most expensive medicine ever, for a rare disorder that destroys…
